Literature DB >> 9625268

Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans.

M Katashima1, K Yamamoto, Y Tokuma, T Hata, Y Sawada, T Iga.   

Abstract

The relationship between plasma concentrations and inhibitory effects on gastric acid secretion by proton pump inhibitors (PPIs) omeprazole (OPZ), lansoprazole (LPZ) and pantoprazole (PPZ), was analyzed using a pharmacokinetic/pharmacodynamic (PK/PD) model in humans. The estimated values of apparent reaction rate constant of PPI and H+,K+-ATPase (K) were 1.34 +/- 0.17 (microM(-1) x h(-1)), 0.339 +/- 0.002 and 0.134 +/- 0.006 for OPZ, LPZ and PPZ, respectively. The estimated values of apparent turn-over rate constant of H+,K+-ATPase (k) were 0.0252 +/- 0.0019 (h(-1)), 0.0537 +/- 0.0006 and 0.0151 +/- 0.0002 for OPZ, LPZ and PPZ, respectively. The apparent dissociation constants of the H+,K+-ATPase-PPI complex (k/K x fp) corrected with plasma free fraction (fp) were about 1 nM for OPZ and LPZ and 2.3 nM for PPZ. Therefore, the potency of the inhibitory effect of PPZ on acid secretion may be slightly weaker than that of OPZ or LPZ. The apparent half lives (ln2/k) of the inhibitory effect on acid secretion were 12.9 h for LPZ, < 27.5 h for OPZ, and < 45.9 h for PPZ, the recovery rate of the inhibitory effect of PPZ on acid secretion was slowest among these PPIs. In conclusion, the relationship between plasma concentrations and inhibitory effects of PPIs on gastric acid secretion could be analyzed by the PK/PD model.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9625268     DOI: 10.1007/BF03189822

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.569


  29 in total

1.  Comparison of once-daily intravenous and oral omeprazole on pentagastrin-stimulated acid secretion in duodenal ulcer patients.

Authors:  C Cederberg; T Lind; K Röhss; L Olbe
Journal:  Digestion       Date:  1992       Impact factor: 3.216

Review 2.  The mechanism and structure of the gastric H,K-ATPase.

Authors:  E C Rabon; M A Reuben
Journal:  Annu Rev Physiol       Date:  1990       Impact factor: 19.318

Review 3.  The physiology of gastric acid secretion.

Authors:  M M Wolfe; A H Soll
Journal:  N Engl J Med       Date:  1988-12-29       Impact factor: 91.245

Review 4.  The continuing development of gastric acid pump inhibitors.

Authors:  G Sachs; J M Shin; M Besancon; C Prinz
Journal:  Aliment Pharmacol Ther       Date:  1993       Impact factor: 8.171

Review 5.  Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.

Authors:  D McTavish; M M Buckley; R C Heel
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

6.  Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats.

Authors:  H Satoh; N Inatomi; H Nagaya; I Inada; A Nohara; N Nakamura; Y Maki
Journal:  J Pharmacol Exp Ther       Date:  1989-02       Impact factor: 4.030

Review 7.  Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

8.  Acid inhibitory characteristics of omeprazole in man.

Authors:  C Cederberg; G Ekenved; T Lind; L Olbe
Journal:  Scand J Gastroenterol Suppl       Date:  1985

Review 9.  Proton pump inhibitors: new drugs and indications.

Authors:  J M Mears; B Kaplan
Journal:  Am Fam Physician       Date:  1996-01       Impact factor: 3.292

10.  Membrane topology and omeprazole labeling of the gastric H+,K(+)-adenosinetriphosphatase.

Authors:  M Besancon; J M Shin; F Mercier; K Munson; M Miller; S Hersey; G Sachs
Journal:  Biochemistry       Date:  1993-03-09       Impact factor: 3.162

View more
  9 in total

Review 1.  Catching the Zebra: Clinical Pearls and Pitfalls for the Successful Diagnosis of Zollinger-Ellison Syndrome.

Authors:  Aaron H Mendelson; Mark Donowitz
Journal:  Dig Dis Sci       Date:  2017-08-03       Impact factor: 3.199

Review 2.  Gastric H,K-ATPase as a drug target.

Authors:  Jai Moo Shin; George Sachs
Journal:  Dig Dis Sci       Date:  2006-04-28       Impact factor: 3.199

3.  Inhibition of pentagastrin-stimulated gastric acid secretion by pantoprazole and omeprazole in healthy adults.

Authors:  Vijaya S Pratha; Daniel L Hogan; James R Lane; Paul J Williams; Michael S Burton; Richard B Lynn; Robyn G Karlstadt
Journal:  Dig Dis Sci       Date:  2006-01       Impact factor: 3.199

Review 4.  Molecular mechanisms in therapy of acid-related diseases.

Authors:  J M Shin; O Vagin; K Munson; M Kidd; I M Modlin; G Sachs
Journal:  Cell Mol Life Sci       Date:  2008-01       Impact factor: 9.261

Review 5.  The concept of complete remission of gastro-oesophageal reflux disease : comparative efficacy of pantoprazole and esomeprazole using the ReQuest questionnaire.

Authors:  Alan B R Thomson
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

Review 6.  The gastric HK-ATPase: structure, function, and inhibition.

Authors:  Jai Moo Shin; Keith Munson; Olga Vagin; George Sachs
Journal:  Pflugers Arch       Date:  2008-06-06       Impact factor: 3.657

7.  Gastric acid secretion in the dog: a mechanism-based pharmacodynamic model for histamine stimulation and irreversible inhibition by omeprazole.

Authors:  Angela Abelö; Björn Holstein; Ulf G Eriksson; Johan Gabrielsson; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-08       Impact factor: 2.745

Review 8.  Pharmacology of proton pump inhibitors.

Authors:  Jai Moo Shin; George Sachs
Journal:  Curr Gastroenterol Rep       Date:  2008-12

9.  Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures.

Authors:  Valentina Shakhnovich; P Brian Smith; Jeffrey T Guptill; Laura P James; David N Collier; Huali Wu; Chad E Livingston; Jian Zhao; Gregory L Kearns
Journal:  J Pediatr       Date:  2018-02       Impact factor: 6.314

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.